논문 목록
11건 · 최신순-
DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia: Clinical Insights from a Real-World Early Experience Program.
[BACKGROUND] DaxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin (BoNT) formulated with a custom-engineered peptide, was recently approved for treating cervical dystonia (CD). DAXI demonstrated a long duration of symptom relie…
-
A randomized, double-blind, placebo-controlled trial of DaxibotulinumtoxinA for Injection for the treatment of upper limb spasticity in adults after stroke or traumatic brain injury.
[BACKGROUND] Intramuscular injection of botulinum toxin type A is a first-line pharmacotherapy for adults with upper limb spasticity (ULS). However, reemergence of symptoms within 12 weeks of treatment is common and longer-lasting treatment…
-
Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinA.
The therapeutic efficacy remaining from prior treatments with botulinum toxins (BoNTs) when cervical dystonia (CD) patients prefer to be re-treated has not been well characterized. Here, we assessed the residual therapeutic efficacy of BoNT…
-
Reply to Trosch et al. Comment on "Dashtipour et al. Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. 2024, , 442".
We thank Trosch et al [...].…
-
Efficacy and safety of DaxibotulinumtoxinA for injection in adults with cervical dystonia: Pooled global analysis of ASPEN-1 and ASPEN-1-CN randomized trials.
[BACKGROUND] DaxibotulinumtoxinA for injection (DAXI), the first long-acting botulinum toxin (BoNT) type A, is FDA approved for cervical dystonia (CD). DAXI's novel formulation, which includes a custom-engineered peptide, is designed to pro…
-
Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information.
The first-line management of cervical dystonia (CD) symptoms is intramuscular injection of botulinum toxin type A (BoNTA). However, a comparison of safety among BoNTAs is difficult because, per regulatory authorities, units of BoNTA activit…
-
Cost Efficiency Analysis for Spasticity Management Based on Physician Botulinum Toxin Prescribing Habits.
[OBJECTIVE] To estimate differences in botulinum toxin type A (BoNT-A) treatment costs per patient for spasticity-injecting physicians, with a focus on physicians' use of alternative BoNT-A agents other than onabotulinumtoxinA. [DESIGN] Re…
-
Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population.
The Centers for Medicare & Medicaid Services (CMS) is the single largest payer for health care in the United States and the largest payer by spending globally. Medicare Part B, with more than 50 million beneficiaries, currently has no broad…
-
Real-World Six-Year National Cost-Minimization Analysis of IncobotulinumtoxinA and OnabotulinumtoxinA in the VA/DoD Healthcare Systems.
[PURPOSE] This study sought to perform a real-world, long-term cost-minimization analysis for incobotulinumtoxinA (Xeomin) versus onabotulinumtoxinA (Botox), given the established non-inferiority when utilized at similar doses. [METHODS] T…
-
Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database.
[INTRODUCTION] Published literature on overdoses related to botulinum toxin A (BtxA) agents is scarce. [OBJECTIVE] The aim of this study was to assess the BtxA drug class' respective agents for associations with overdose. [METHODS] United…
- Response to "Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database".